Brief: Celyad Oncology Presents Preclinical Data On Allogeneic Car T Therapy Program

Celyad Oncology SA

12/11/2021 12:06

Nov 12 (Reuters) - Celyad Oncology SA  CYAD.BR :
    * CELYAD ONCOLOGY PRESENTS PRECLINICAL DATA ON ALLOGENEIC
CAR T
THERAPY PROGRAM AND HIGHLIGHTS KEYNOTE-B79 CLINICAL TRIAL DESIGN
AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 36TH ANNUAL
MEETING
    * PRECLINICAL DATA SUPPORT ARMORING NKG2D CAR T CELLS WITH
IL-18
TO DRIVE IMPROVED ANTI-TUMOR ACTIVITY OF PRODUCT CANDIDATE
    * DEVELOPMENT CONTINUES FOR SECOND-GENERATION MULTIPLEXING
SHRNA
SCAFFOLD FOR NOVEL NON-GENE EDITED CAR T CANDIDATES WITH DESIRED
PHENOTYPES
    * KEYNOTE-B79 PHASE 1B TRIAL EVALUATING CYAD-101 WITH
KEYTRUDA
(PEMBROLIZUMAB) IN PATIENTS WITH MICROSATELLITE STABLE MCRC SET
TO START IN Q4 2021

Source text for Eikon:  ID:nGNX15MXnc 
Further company coverage:  CYAD.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))